NeuroMab™ Anti-CD284 Antibody(NRP-0422-P745)

Figure 1 is a graph depicting the binding of a murine monoclonal antibody (referred to herein as "7E3") to the TLR4/MD-2 complex.

Binding specificity was shown by flow cytometry using mock-transfected or TLR4/MD-2-transfected cells.

Figure 2 is a graph depicting inhibition of lipopolysaccharide (LPS)-induced IL-8 production in TLR4/MD-2 transfected HEK 293 cells by monoclonal antibody mu7E3.

Binding specificity was shown by flow cytometry using mock-transfected or TLR4/MD-2-transfected cells.

Figure 3 depicts inhibition of LPS-induced IL-6 production in human whole blood by monoclonal antibody mu7E3.

Binding specificity was shown by flow cytometry using mock-transfected or TLR4/MD-2-transfected cells.

Figure 4 is a series of graphs depicting the specificity of the mu7E3 monoclonal antibody for the TLR4/MD-2 complex.

The specificity of mu7E3 antibody was determined by flow cytometry on HEK 293 cells transiently transfected with mock vector (Panel A), human TLR4 (Panel B), human TLR4 and human MD-2 (Panel C), rabbit TLR4 and rabbit Analysis revealed MD-2 (panel D).

Figure 5 is a graph illustrating the ability of the VH and VL nucleotide sequences of mu7E3 expressed as a chimeric MAb ("chimeric 7E3") to specifically bind human TLR4/MD-2 complexes on the surface of transfected CHO cells.

The specificity of mu7E3 antibody was determined by flow cytometry on HEK 293 cells transiently transfected with mock vector (Panel A), human TLR4 (Panel B), human TLR4 and human MD-2 (Panel C), rabbit TLR4 and rabbit Analysis revealed MD-2 (panel D).

Figure 6 is a graph depicting inhibition of lipopolysaccharide (LPS)-induced IL-8 production by chimeric 7E3 MAb in TLR4/MD-2 transfected HEK 293 cells.

Cells were incubated with the indicated concentrations of chimeric 7E3 or an isotype-matched MAb control followed by incubation with LPS (15 ng/ml). IL-8 levels were assessed 16 hours after LPS treatment.